

## AN ACT

1 Providing for prescribing and dispensing drugs approved by the  
2 United States Food and Drug Administration for off-label use  
3 to treat coronavirus infections causing respiratory-syndrome-  
4 related illnesses.

5 The General Assembly of the Commonwealth of Pennsylvania  
6 hereby enacts as follows:

7 Section 1. Short title.

8 This act shall be known and may be cited as the Coronavirus  
9 Infection Medication Act.

10 Section 2. Definitions.

11 The following words and phrases when used in this act shall  
12 have the meanings given to them in this section unless the  
13 context clearly indicates otherwise:

14 "Coronavirus." Any of the various RNA-containing spherical  
15 viruses of the family coronaviridae.

16 "Dispense." The preparation of a prescription or  
17 nonprescription drug in a suitable container appropriately  
18 labeled for subsequent administration to or use by a patient or

1 other individual authorized to receive the drug.

2 "Licensing board or commission." An administrative board or  
3 commission under the Bureau of Occupational and Professional  
4 Affairs in the Department of State.

5 "Pharmacist." As defined in section 2(10) of the act of  
6 September 27, 1961 (P.L.1700, No.699), known as the Pharmacy  
7 Act.

8 "Prescriber." A person who is licensed, registered or  
9 otherwise lawfully authorized to prescribe a controlled  
10 substance or any other drug or device in the course of  
11 professional practice or research in this Commonwealth.

12 Section 3. Drugs for off-label use to treat coronavirus  
13 infections causing respiratory-syndrome-related  
14 illnesses.

15 (a) Authorization.--A prescriber may prescribe, and a  
16 pharmacist shall dispense, in accordance with a prescription  
17 drug order and with the informed consent of a patient, a  
18 therapeutic drug approved by the United States Food and Drug  
19 Administration, including hydroxychloroquine sulfate and  
20 ivermectin, for off-label use to the patient for prophylaxis or  
21 for at-home, early-stage outpatient or hospital inpatient  
22 treatment of coronavirus infections causing respiratory-  
23 syndrome-related illnesses.

24 (b) Exposure not required.--A patient's suspected exposure  
25 to coronavirus infections causing respiratory-syndrome-related  
26 illnesses shall not be required for a prescriber to prescribe,  
27 and a pharmacist to dispense, a drug to the patient for  
28 prophylaxis as authorized under subsection (a).

29 (c) Screening not required.--A patient's positive screening  
30 results test shall not be required for a prescriber to

1 prescribe, and a pharmacist to dispense, a drug to the patient  
2 for at-home, early-stage outpatient treatment as authorized  
3 under subsection (a).

4 Section 4. Administrative or disciplinary actions.

5 An action taken by a prescriber or pharmacist in accordance  
6 with section 3 shall not be considered unlawful, unethical,  
7 unauthorized or unprofessional conduct by a licensing board or  
8 commission. A licensing board or commission may not take an  
9 administrative or disciplinary action against a prescriber or  
10 pharmacist for an action taken in accordance with section 3.

11 Section 5. Effective date.

12 This act shall take effect immediately.